The field of pharmacogenomics has experienced an unprecedented and exponential progress in recent years. Several pharmacogenomic biomarkers have been identified that have clinical practical value for the effective management of multiple pathologic disorders. Pharmacogenomic biomarkers sometimes help estimate the therapeutic window for specific patient populations and thereby help maximize patient safety. Translation of preclinical research discoveries in this expanding field into meaningful clinical diagnostic and therapeutic advances, especially in the context of precision medicine, is a focal point of contemporary research efforts. A better understanding of the genetic and epigenetic influencers of clinical responses to therapeutic agents is of paramount importance.
On one hand, much remains to be deciphered and discovered through breakthrough research. On the other hand, existing information needs to be better disseminated to become part of the clinical decision process. In addition, there is a need for complementary health economics research to support the implementation of these validated biomarkers in routine clinical practice. Ultimately, these efforts are likely to improve treatment outcomes even in difficult-to-treat disease and provide the foundation for more effective personalized treatment strategies for a broad-spectrum of illnesses.
For this important Research Topic, we invite the research community to submit Original Research as well as Review articles across all aspects of the pharmacogenomics discovery and implementation, including, but not limited to:
- Studies exploring new genetics biomarkers on drug response (considered as changes in efficacy and/or adverse drug reactions)
- Studies reviewing the evidence of pharmacogenomics biomarkers
- Studies covering the clinical implementation of already validated pharmacogenomics biomarkers
- Studies of cost-effectiveness of pharmacogenetic biomarkers implementation
Articles acceptable for this Research Topic are limited to:
-Articles unambiguously related to Pharmacogenetics, Pharmacogenomics, drug metabolism or drug transport
-If patient data are analyzed, a comprehensive description of the patients – including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities as well as additional clinical information and assessment of drug response/effects should be included.
-If genetics, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for the section of the specific data should be provided.
-Studies related to natural compounds, herbal extracts, or traditional medicine products will not be included in this Research Topic.
The field of pharmacogenomics has experienced an unprecedented and exponential progress in recent years. Several pharmacogenomic biomarkers have been identified that have clinical practical value for the effective management of multiple pathologic disorders. Pharmacogenomic biomarkers sometimes help estimate the therapeutic window for specific patient populations and thereby help maximize patient safety. Translation of preclinical research discoveries in this expanding field into meaningful clinical diagnostic and therapeutic advances, especially in the context of precision medicine, is a focal point of contemporary research efforts. A better understanding of the genetic and epigenetic influencers of clinical responses to therapeutic agents is of paramount importance.
On one hand, much remains to be deciphered and discovered through breakthrough research. On the other hand, existing information needs to be better disseminated to become part of the clinical decision process. In addition, there is a need for complementary health economics research to support the implementation of these validated biomarkers in routine clinical practice. Ultimately, these efforts are likely to improve treatment outcomes even in difficult-to-treat disease and provide the foundation for more effective personalized treatment strategies for a broad-spectrum of illnesses.
For this important Research Topic, we invite the research community to submit Original Research as well as Review articles across all aspects of the pharmacogenomics discovery and implementation, including, but not limited to:
- Studies exploring new genetics biomarkers on drug response (considered as changes in efficacy and/or adverse drug reactions)
- Studies reviewing the evidence of pharmacogenomics biomarkers
- Studies covering the clinical implementation of already validated pharmacogenomics biomarkers
- Studies of cost-effectiveness of pharmacogenetic biomarkers implementation
Articles acceptable for this Research Topic are limited to:
-Articles unambiguously related to Pharmacogenetics, Pharmacogenomics, drug metabolism or drug transport
-If patient data are analyzed, a comprehensive description of the patients – including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities as well as additional clinical information and assessment of drug response/effects should be included.
-If genetics, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for the section of the specific data should be provided.
-Studies related to natural compounds, herbal extracts, or traditional medicine products will not be included in this Research Topic.
